Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug

(2013) J. M. Rowe et al.   BLOOD

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML

(2013) N. Shayegi et al.   BLOOD

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

(2013) M. S. Kung Sutherland et al.   BLOOD

Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia

(2013) Brigitte Mohr et al.   BRITISH JOURNAL OF HAEMATOLOGY

Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system

(2013) C Arndt et al.   LEUKEMIA

Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells

(2013) C Arndt et al.   LEUKEMIA

Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia

(2012) Keumrock Hwang et al.   ANNALS OF HEMATOLOGY

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML

(2012) J. A. Pollard et al.   BLOOD

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

(2012) R. B. Walter et al.   BLOOD

The Origin and Evolution of Mutations in Acute Myeloid Leukemia

(2012) John S. Welch et al.   CELL

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

(2012) Sylvie Castaigne et al.   LANCET

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct

(2012) M Aigner et al.   LEUKEMIA

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

(2012) A K Burnett et al.   LEUKEMIA

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

(2012) Li Ding et al.   NATURE

Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations

(2011) Roberta Riccioni et al.   BRITISH JOURNAL OF HAEMATOLOGY

Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia

(2011) Nicolas Goardon et al.   CANCER CELL

High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation

(2011) M. S. De Propris et al.   HAEMATOLOGICA

Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System

(2011) Christoph Röllig et al.   JOURNAL OF CLINICAL ONCOLOGY

Cytarabine Dose of 36 g/m2Compared With 12 g/m2Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study

(2011) Markus Schaich et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Stem cell gene expression programs influence clinical outcome in human leukemia

(2011) Kolja Eppert et al.   NATURE MEDICINE

Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34- fraction

(2010) D. C. Taussig et al.   BLOOD

Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells

(2010) Christoph Stein et al.   BRITISH JOURNAL OF HAEMATOLOGY

A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting

(2010) Markus Kügler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Current and emerging therapies for acute myeloid leukemia

(2010) Tadeusz Robak et al.   CLINICAL THERAPEUTICS

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Monoclonal Antibody-Mediated Targeting of CD123, IL-3 Receptor α Chain, Eliminates Human Acute Myeloid Leukemic Stem Cells

(2009) Liqing Jin et al.   Cell Stem Cell

Targeted Elimination of Leukemia Stem Cells; a New Therapeutic Approach in Hemato-Oncology

(2009) B. Cate et al.   CURRENT DRUG TARGETS

HLA-DRnegpatients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia

(2009) Uta Oelschlaegel et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Anthracycline Dose Intensification in Acute Myeloid Leukemia

(2009) Hugo F. Fernandez et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD33 Detection by Immunohistochemistry in Paraffin-Embedded Tissues

(2008) James D. Hoyer et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells

(2008) D. C. Taussig et al.   BLOOD

Persistence of CD33 expression at relapse in CD33+acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease

(2008) Patrice Chevallier et al.   BRITISH JOURNAL OF HAEMATOLOGY

Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor

(2008) Roberta Riccioni et al.   BRITISH JOURNAL OF HAEMATOLOGY